Status and phase
Conditions
Treatments
About
The goal of this clinical trial is to find out if Five-fraction CyberKnife stereotactic body radiation therapy (SBRT) with real-time Synchrony® motion tracking can treat ultra-central nonsmall cell lung cancer while reducing the amount of serious side effects from SBRT. Participants will
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Patients aged 18 or older.
Patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
Patients with confirmed tumor location using advanced imaging to ensure accurate classification of ultra-central NSCLC.
Ability to undergo bronchoscopy and Endobronchial ultrasound (EBUS) with adequate fiducial placement
Histologically or cytologically confirmed clinical stage T1-T2 N0 M0 NSCLC (AJCC 9th edition), with maximum tumor diameter ≤5 cm.
Absence of overt radiological or bronchoscopy assessed gross endobronchial invasion, invasion of the trachea, esophagus, major blood vessels, or other mediastinal structures.
4D-CT (computed tomography) scans will be required to evaluate tumor motion and verification at time of simulation:
○ Screening for ultra-central tumor deformation between inhalation and exhalation extremities will be performed via 4D-CT to avoid inappropriate margins for significant tumor motion or deformation.
Ultra-central tumors must include:
o Gross Tumor Volume (GTV) or Planning Target Volume (PTV) located within 1 cm (centimeter) of the Proximal Bronchial Tree (PBT) and/or at least one of the following: (1) GTV or protocol PTV within 1 cm of the PBT; or (2) GTV within 5 mm of or abutting/overlapping the esophagus, heart/pericardium, aorta, pulmonary artery, or pulmonary vein.
Patients are eligible to receive SBRT:
Patients are eligible to receive radiation therapy:
Female patients of childbearing potential must have a negative pregnancy test prior to treatment and agree to contraception during and for a defined period after treatment.
Patients who can comply with follow-up visits and treatment plans.
Patients who can provide written informed consent prior to study procedures.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
35 participants in 1 patient group
Loading...
Central trial contact
Jonathan Lischalk, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal